Takeda announces approval of nuvaxovid® covid-19 vaccine for primary and booster immunization in japan

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that it has received manufacturing and marketing approval from the japan ministry of health, labour and welfare (mhlw) for nuvaxovid® intramuscular injection (nuvaxovid), a novel recombinant protein-based covid-19 vaccine, for primary and booster immunization in individuals aged 18 and older. novavax licensed and transferred its manufacturing technologies to enable takeda to develop and manufacture the
TAK Ratings Summary
TAK Quant Ranking